This study tested a relatively new drug, PCSK9 inhibitors, which lower LDL cholesterol/ApoB above and beyond what's possible with statins and ezetimibe.

The patient population was 3600 people with high-risk diabetes, but not atherosclerosis. So they're at elevated risk compared to the average person.

PCSK9 inhibitors are still expensive (about $1,800 per year), with pretty limited insurance coverage. But this will likely change as the evidence builds.